理解临床实施协调员在部署循证干预中的经验
本研究基于FIRST试验,该试验通过电子健康记录最佳实践警示(BPA)实施氟喹诺酮类抗生素预授权以优化急性护理环境用药。研究对临床实施协调员进行半结构化访谈、实施日记和签到会议的内容分析,描述其在抗菌药物管理团队中的角色职责及实施过程中的促进与障碍因素。
要点
- 临床实施协调员承担信息收集、BPA设计准备、人员培训、会议组织、利益相关者联络、临床疗效评估及临床参与等多重角色。
- 主要障碍包括组织人员配置模式和COVID-19中断。
- 促进因素包括抗菌药物管理团队赋权、与员工及监督治理委员会的良好关系、采用多样化实施策略。
核心结论
- 临床实施协调员通过其角色和职责促进实施过程,并作为战略伙伴提高氟喹诺酮预授权方案的采纳和可持续性。
研究设计与样本
- 对半结构化访谈、实施日记和签到会议进行定向内容分析,采用Urquhart等的中层管理者在医疗创新实施中角色的概念框架。
主要发现
- 临床实施协调员执行多种角色,包括为BPA设计收集和汇编信息、准备员工、组织会议、连接相关利益相关者、评估临床疗效以及作为临床医生参与创新。
- 协调员识别组织人员配置模式和COVID-19中断为主要障碍。
- 促进因素包括抗菌药物管理团队赋权、与员工和监督/治理委员会的良好关系以及使用多样化的实施策略。
临床怎么用
- 在实施医疗创新时,可考虑设置临床实施协调员角色以促进实施过程并提高方案采纳和可持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The fluoroquinolone restriction for the prevention of Clostridioides difficile infection (FIRST) trial is a multisite clinical study in which sites carry out a preauthorization process via electronic health record-based best-practice alert (BPA) to optimize the use of fluoroquinolone antibiotics in acute care settings. Our research team worked closely with clinical implementation coordinators to facilitate the dissemination and implementation of this evidence-based intervention. Clinical implementation coordinators within the antibiotic stewardship team (AST) played a pivotal role in the implementation process; however, considerable research is needed to further understand their role. In this study, we aimed to (1) describe the roles and responsibilities of clinical implementation coordinators within ASTs and (2) identify facilitators and barriers coordinators experienced within the implementation process. METHODS: We conducted a directed content analysis of semistructured interviews, implementation diaries, and check-in meetings utilizing the conceptual framework of middle managers' roles in innovation implementation in healthcare from Urquhart et al. RESULTS: Clinical implementation coordinators performed a variety of roles vital to the implementation's success, including gathering and compiling information for BPA design, preparing staff, organizing meetings, connecting relevant stakeholders, evaluating clinical efficacy, and participating in the innovation as clinicians. Coordinators identified organizational staffing models and COVID-19 interruptions as the main barriers. Facilitators included AST empowerment, positive relationships with staff and oversight/governance committees, and using diverse implementation strategies. CONCLUSION: When implementing healthcare innovations, clinical implementation coordinators facilitated the implementation process through their roles and responsibilities and acted as strategic partners in improving the adoption and sustainability of a fluoroquinolone preauthorization protocol.
引用
- Hernandez SE, Solomon D, Moon J, et al. Understanding clinical implementation coordinators' experiences in deploying evidence-based interventions. Am J Health Syst Pharm. 2024. PMID: 37897218. doi:10.1093/ajhp/zxad272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。